Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...

Family carers provide vital support in the home to loved ones living with additional needs, chronic illnesses, disabilities, ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressin ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...

The board of Eli Lilly and Company (NYSE:LLY) has announced that it will be paying its dividend of $1.50 on the 10th of March, an increased payment from last year's comparable dividend.